Form 4: CVS Director Michael Mahoney Acquires Deferred Stock Units
Director Compensation Disclosure
CVS Health Director Michael F. Mahoney acquired 1,737.0046 deferred stock units as part of the company's non-employee director compensation plan.
Summary
- Director Michael F. Mahoney received 1,737.0046 deferred stock units (DSUs) on May 14, 2026.
- The units were issued in lieu of a semi-annual cash retainer for board service.
- The transaction was valued at $97.15 per share.
- Following this transaction, the director holds a total of 6,428.8174 shares in the form of deferred stock units.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.
Positives
- Demonstrates alignment of director interests with shareholders through equity-based compensation.
- Reflects standard corporate governance practice for non-employee director compensation.
Negatives
- None identified.
Risks
- None identified.
Future Outlook
The deferred stock units will be converted into common stock at a future date as elected by the reporting person, per the 2017 Incentive Compensation Plan.
Industry Context
StockSavvy.ai notes that this is a routine disclosure of director compensation, common among large-cap healthcare companies to ensure board members maintain a financial stake in the company's long-term performance.
Comparison to Industry Standards
- The use of deferred stock units for director retainers is a standard practice among S&P 500 companies to align board incentives with shareholder value.
- The transaction follows typical governance protocols for CVS Health and its peers in the retail pharmacy and healthcare services sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Issuance of deferred stock units in lieu of semi-annual cash retainer. | 05/14/2026 | Neutral; standard alignment of director compensation with equity performance. |
Stakeholder Impact
- Shareholders: Minimal impact; reflects standard board compensation practices.
Next Steps
- Conversion of deferred stock units into common stock at the director's future election.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Date of the transaction involving deferred stock units. |
| 05/15/2026 | Date the Form 4 was signed and filed. |
Keywords
CVS Health, Insider Trading, Form 4, Director Compensation, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.